

### TECHNICAL BULLET U.S. NATIONAL LIBRARY OF MEDICINE I NATIONAL INSTITUTES OF HEALTH

#### Articles

### Upcoming PubMed, TOXNET, and Teaching with Technology Classes e8 2012 June 11 [posted]

#### **PubMed Discovery Tools**

2012 June 08 [posted] 2012 June 18 [Editor's note added] e/ 2013 April 23 [Editor's note added]

MLA 2012 - e6a-e MLA 2012: NLM Theater Presentations MLA 2012: NLM Online Users' Meeting: **PowerPoint Presentations** MLA 2012: DOCLINE Users' Group Meeting: PowerPoint Presentation MLA 2012: NLM Update PowerPoint Presentations MLA 2012: NLM Online Users' Meeting: Questions and Answers

#### New Look, New Collections for IndexCat Database

e5 2012 May 22 [posted]

UMLS 2012AA Release Available e4 2012 May 07 [posted]

### PubMed Filters Sidebar Replaces

the Limits Page e3 2012 May 02 [posted] 2012 May 10 [Editor's note added] 2012 May 15 [Editor's note added]

#### **PubMed and Computed Author** Sorted Display

2012 May 02 [posted] 2012 May 10 [Editor's note added] 2013 November 25 [Figure replaced] e2

**NLM Classification 2012 Edition Now Available** e1 2012 May 01 [posted]

### In Brief

**Drug Information Portal Now** Available for Mobile Devices 2012 June 25 [posted]

Redesigned Web and Mobile Versions of Haz-Map b6 2012 June 21 [posted]

#### 2012AA UMLS Release Available on UTS

b5 2012 June 11 [posted]

UMLS Fact Sheets Updated b4 2012 June 11 [posted]

ICD-9-CM to SNOMED CT Map b3 2012 May 17 [posted]

UTS API 2.0 Beta Launch b2 2012 May 07 [posted]

New LinkOut FAQ: What is the publication date type (pdat drop-down menu) and how do I use it?

b1 2012 May 01 [posted]

#### **NLM News Announcements**

NLM Announces the Public Release of the Papers of John B. Calhoun, Noted NIH Researcher in Social **Crowding and Aggression** 2012 June 20

**NLM Invites Nominations for** IHTSDO Standing Committees Due June 29, 2012 2012 June 06

ADA (SNODENT) and IHTSDO (SNOMED CT) Agree to Licensing Arrangements 2012 June 06

**NISO Seeks Public Comment on Draft Recommended Practice PIE-J:** Presentation & Identification of **E-Journals** 2012 May 30

National Library of Medicine Releases Free iPad App, "Native Voices: Native Peoples' Concepts of Health and Illness" 2012 May 16

#### Updated Web

#### Resources

Branching Out: The MeSH® Vocabulary Updated 2012 May 30

UMLS Forthcoming **Releases Updated** 2012 May 23

PubMed Tutorial Updated 2012 May 10

LinkOut for Libraries **Training and Educational** Resources 2012 May 01

#### **Most Popular**

PubMed Filters Sidebar Replaces the Limits Page

PubMed Results and Citation Manager Software

PubMed and the My NCBI **Favorites Collection** Feature

2012 MAY-JUNE No. 386 Issue Completed June 27, 2012

ISSN 2161-2986 (Online) Content not copyrighted; freely reproducible.

Trademarks Copyright Privacy Accessibility Contact NLM Viewers and Players U.S. National Library of Medicine 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health NIH ... Turning Discovery into Health® U.S. Department of Health and Human Services Freedom of Information Act

Last updated: 25 November 2013 Permanence level: Permanent: Stable Content



### **Drug Information Portal Now Available for Mobile Devices**

Drug Information Portal Now Available for Mobile Devices

#### **2012 June 25** [posted]

The NLM Drug Information Portal is now available for mobile devices.

This mobile optimized Web site covers over 32,000 drugs and provides descriptions, drug names, pharmaceutical categories, and structural diagrams. Each record also features information links to nineteen other resources including PubMed, LactMed, and Drugs@FDA. The mobile version of a resource is used when available.

Smart Phones accessing the main Drug Portal site will be taken the mobile site. The Drug Information Portal is a free Web resource from the NLM that provides an informative, user friendly entry-way to current drug information for over 32,000 drugs. Links to sources span the breadth of the NLM, the National Institutes of Health (NIH), and other government agencies. Current information regarding consumer health, clinical trials, AIDS-related drug information, MeSH pharmacological actions, PubMed biomedical literature, and physical properties and structure is easily retrieved by searching on a drug name. A varied selection of focused topics in medicine and drug-related information is also available from displayed subject headings.

Please send comments and suggestions to: tehip@teh.nlm.nih.gov.

ISSN 2161-2986 (Online) Content not copyrighted; freely reproducible.

Trademarks Copyright Privacy Accessibility Contact NLM Viewers and Players U.S. National Library of Medicine 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health *NIH...Turning Discovery into Health*® U.S. Department of Health and Human Services Freedom of Information Act

Last updated: 01 November 2013 Permanence level: Permanent: Stable Content



### **Redesigned Web and Mobile Versions of Haz-Map**

Redesigned Web and Mobile Versions of Haz-Map. NLM Tech Bull. 2012 May-Jun;(386):b6.

#### **2012 June 21** [posted]

The Division of Specialized Information Services released redesigned Web and mobile versions of Haz-Map. The new design adapts to Web browsers on desktop computers, laptops, and tablets, as well as mobile browsers on smart phones, such as iPhones, Android and Blackberry phones.

Haz-Map is an occupational health database designed for health and safety professionals and for consumers seeking information about the health effects of exposure to chemicals and biologicals at work. Haz-Map links jobs and hazardous tasks with occupational diseases and their symptoms. It currently covers over 5,997 chemical and biological agents and 235 occupational diseases.

For more information see the Haz-Map Fact Sheet.

ISSN 2161-2986 (Online) Content not copyrighted; freely reproducible.

Trademarks Copyright Privacy Accessibility Contact NLM Viewers and Players U.S. National Library of Medicine 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health *NIH...Turning Discovery into Health*®

U.S. Department of Health and Human Services Freedom of Information Act

Last updated: 01 November 2013 Permanence level: Permanent: Stable Content



### **2012AA UMLS Release Available on UTS**

2012AA UMLS Release Available on UTS. NLM Tech Bull. 2012 May-Jun;(386):b5.

#### **2012 June 11** [posted]

You may now browse the 2012AA Unified Medical Language System (UMLS) Release on the UMLS Terminology Services (UTS) from the *Applications* menu, Metathesaurus Browser.

**ISSN 2161-2986 (Online)** Content not copyrighted; freely reproducible. Trademarks Copyright Privacy Accessibility Contact NLM Viewers and Players U.S. National Library of Medicine 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health *NIH...Turning Discovery into Health*® U.S. Department of Health and Human Services Freedom of Information Act

Last updated: 15 June 2012 Permanence level: Permanent: Stable Content



### **UMLS Fact Sheets Updated**

UMLS Fact Sheets Updated. NLM Tech Bull. 2012 May-Jun;(386):b4.

**2012 June 11** [posted]

The six fact sheets in the Unified Medical Language System (UMLS) series were updated:

UMLS MetamorphoSys UMLS Metathesaurus UMLS Semantic Network UMLS Specialist Lexicon UMLS Terminology Services Unified Medical Language System (UMLS)

ISSN 2161-2986 (Online) Content not copyrighted; freely reproducible.

Trademarks Copyright Privacy Accessibility Contact NLM Viewers and Players U.S. National Library of Medicine 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health *NIH...Turning Discovery into Health*® U.S. Department of Health and Human Services Freedom of Information Act

Last updated: 11 June 2012 Permanence level: Permanent: Stable Content



### **ICD-9-CM to SNOMED CT Map**

ICD-9-CM to SNOMED CT Map. NLM Tech Bull. 2012 May-Jun;(386):b3.

#### 2012 May 17 [posted]

The new ICD-9-CM to SNOMED CT Map is available for download by UMLS licensees. The map will facilitate the translation of legacy ICD-9-CM data to SNOMED CT and aid the transition to use of SNOMED CT for patient problem lists. The download consists of two files (one-to-one maps and one-to-many maps), which include usage frequencies of ICD-9-CM codes based on CMS (Centers for Medicare & Medicaid Services) data, and SNOMED CT concepts from the CORE Problem List Subset.

ISSN 2161-2986 (Online) Content not copyrighted; freely reproducible.

Trademarks Copyright Privacy Accessibility Contact NLM Viewers and Players U.S. National Library of Medicine 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health *NIH...Turning Discovery into Health*® U.S. Department of Health and Human Services Freedom of Information Act

Last updated: 17 May 2012 Permanence level: Permanent: Stable Content



### UTS API 2.0 Beta Launch

UTS API 2.0 Beta Launch. NLM Tech Bull. 2012 May-Jun;(386):b2.

#### 2012 May 07 [posted]

The beta version of the UMLS Terminology Services API 2.0 (UTS API 2.0) is now available. The UTS API 2.0 is intended for application developers to perform Web service calls and retrieve UMLS data within their own applications. The UTS API 2.0 provides the ability to search, retrieve, and filter terms, concepts, attributes, relations, metadata and more from over 160 vocabularies of the UMLS Metathesaurus, as well as the Semantic Network. New paging, sorting and filtering (PSF) capabilities allow you to customize results of your Web service calls in many ways: you may choose to include or exclude specific criteria, sort results by fields, or specify results displayed per page. We provide a suite of Web Services Description Language (WSDL) files, API installation instructions, and sample code in the documentation at: https://uts.nlm.nih.gov/home.html#apidocumentation.

The UTS API 2.0 is a replacement for the legacy UTS API, which will be deprecated over the coming months.

ISSN 2161-2986 (Online) Content not copyrighted; freely reproducible.

Trademarks Copyright Privacy Accessibility Contact NLM Viewers and Players U.S. National Library of Medicine 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health *NIH...Turning Discovery into Health*®

U.S. Department of Health and Human Services Freedom of Information Act

Last updated: 01 November 2013 Permanence level: Permanent: Stable Content



# New LinkOut FAQ: What is the publication date type (pdat drop-down menu) and how do I use it?

New LinkOut FAQ: What is the publication date type (pdat drop-down menu) and how do I use it? NLM Tech Bull. 2012 May-Jun;(386):b1.

#### 2012 May 01 [posted]

A new LinkOut FAQ, What is the publication date type (pdat drop-down menu) and how do I use it?, was published. See the article, *Library Submission Utility: Publication Date Type Feature*, for additional information.

**ISSN 2161-2986 (Online)** Content not copyrighted; freely reproducible. Trademarks Copyright Privacy Accessibility Contact NLM Viewers and Players U.S. National Library of Medicine 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health *NIH...Turning Discovery into Health*® U.S. Department of Health and Human Services Freedom of Information Act

Last updated: 01 May 2012 Permanence level: Permanent: Stable Content



### Upcoming PubMed, TOXNET, and Teaching with Technology Classes

Upcoming PubMed, TOXNET, and Teaching with Technology Classes. NLM Tech Bull. 2012 May-Jun; (386):e8.

#### **2012 June 11** [posted]

Trainers from the National Library of Medicine (NLM) and NLM Training Center (NTC) are offering no-cost classes this summer and autumn: "PubMed for Trainers," "TOXNET and Beyond," and "Teaching with Technology: Tips, Techniques and Tools." Classes are open to residents of the U.S. To register, visit the NTC Web site at http://nnlm.gov/ntcc/classes/schedule.html.

#### **PubMed for Trainers**

Would you like to gain new skills, brush up on existing PubMed skills and collaborate with colleagues to help create effective training strategies? PubMed for Trainers is held in four sessions; three online and one in-person session. The class is eligible for 15 hours of MLA CE credit. This hands-on course consists of lectures, individual exercises, group work and discussions in four sessions, with approximately 2-3 hours of independent work.

This hands-on class includes nine presentations created by the National Library of Medicine, interactive demonstrations, hands-on exercises, small group work and networking opportunities. By the end of the course, you should:

- Have a functional knowledge of the MEDLINE database
- Understand behind the scenes details of how PubMed translates your search
- Know how to use Medical Subject Headings (MeSH)
- Customize your search results and save search strategies using My NCBI
- Increase your knowledge of how to search more effectively for drugs, diseases, and patient centered research.

Upcoming Dates (for specific dates of each session, visit the NTC Web site at http://nnlm.gov/ntcc/classes/schedule.html):

- June 28 July 17, 2012: 3 online sessions and in-person session at Worcester, MA
- July 19, 2012 August 6, 2012: 3 online sessions and in-person session at Cincinnati, OH
- September 13, 2012 October 2, 2012: 3 online sessions and in-person session at Kansas City, KS
- October 4, 2012 October 25, 2012: 3 online sessions and in-person session at Bethesda, MD
- October 11, 2012 October 23, 2012: 3 online sessions and in-person session at New York, NY

#### **TOXNET** and Beyond

Learn how to use the NLM Environmental Health and Toxicology Portal by attending a one-day, in-person "TOXNET and Beyond" class. You will learn the basics of searching TOXNET, a Web-based system of databases in the areas of toxicology, environmental health, and related fields. We will also discuss the NLM Environmental Health and Toxicology Portal that provides environmental health resources beyond the TOXNET databases. The class is eligible for six MLA CE credits.

Upcoming Dates:

- August 7, 2012: Cincinnati, OH
- September 12, 2012: Bethesda, MD
- October 24, 2012: New York, NY

#### Teaching with Technology: Tips, Techniques and Tools

In this class, you will learn about using technology tools for teaching distance learning courses. We will discuss options and best practices for asynchronous and synchronous distance classes, as well as "blended" classes that offer both in-person and online options. Adult learning principles will be reviewed. We will examine and discuss

Upcoming PubMed, TOXNET, and Teaching with Technology Classes. NLM Technical Bulletin. 2012 May–Jun

examples of software and Web site tools in teaching.

The class is taught "asynchronously" using the Moodle course management system, so you can complete the classwork at a time convenient for you. Allow approximately two hours per week for independent classwork. There are four weeks of assignments, readings, and discussions, with the fifth week saved for a "catch-up" week. Upon completion of the class you will receive eight MLA CE credits.

Upcoming Dates:

• July 23 - August 27, 2012: Online

#### **Questions?**

If you have questions, contact the NTC at ntc@utah.edu

ISSN 2161-2986 (Online) Content not copyrighted; freely reproducible.

Trademarks Copyright Privacy Accessibility Contact NLM Viewers and Players U.S. National Library of Medicine 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health *NIH...Turning Discovery into Health*® U.S. Department of Health and Human Services Freedom of Information Act

Last updated: 11 June 2012 Permanence level: Permanent: Stable Content



### **PubMed Discovery Tools**

Canese K. PubMed Discovery Tools. NLM Tech Bull. 2012 May-Jun;(386):e7.

2012 June 08 [posted] 2012 June 18 [Editor's note added] 2013 April 23 [Editor's note added]

[Editor's note: These changes were implemented in PubMed on June 18, 2012.]

PubMed "Results by year" and PubMed Central "PMC images search" tools will soon display in the discovery column for all PubMed users (see Figure 1).

Pu	ibMed sars virus	Search
	RSS Save search Advanced	Help
<u>Dis</u>	play Settings: Summary, 20 per page, Sorted by Recently Added Send to: Send to:	Filters: Manage Filters
Re	sults: 1 to 20 of 3050 <	Results by year
□ 1.	The time required to estimate the case fatality ratio of influenza using only the tip of an iceberg: joint estimation of the virulence and the transmission potential. Ejima K, Omori R, Cowling BJ, Aihara K, Nishiura H. Comput Math Methods Med. 2012;2012:978901. Epub 2012 May 10. PMID: 22649483 [PubMed - in process] Related citations	
□ 2.	Comparative in vivo analysis of the nsp15 endoribonuclease of murine, porcine and severe acute respiratory syndrome coronaviruses. Cao J, Zhang X.	PMC Images search for sars
	Virus Res. 2012 May 19. [Epub ahead of print] PMID: 22617024 [PubMed - as supplied by publisher] Related citations	
3.	The Adjuvanticity of an O. volvulus-Derived rOv-ASP-1 Protein in Mice Using Sequential Vaccinations and in Non-Human Primates. Wang J, Tricoche N, Du L, Hunter M, Zhan B, Goud G, Didier ES, Liu J, Lu L, Marx PA, Jiang S, Lustigman S. PLoS One. 2012;7(5):e37019. Epub 2012 May 17. PMID: 22615877 [PubMed - in process] Free PMC Article Related citations	See more (269)

#### Figure 1: PubMed results with "Results by year" and "PMC images search" tools.

[Editor's note: The "Results by year" timeline tool has been changed to display for search results with 1,000 or more citations.]

PubMed Discovery Tools. NLM Technical Bulletin. 2012 May–Jun The "Results by year" timeline tool will display for search results with 10,000 or more citations. Mouseover the bars in the timeline to display the number of citations for each year, click the right and left arrows to display older or newer years, and click the individual bars in the timeline to display the results for a single year (see Figure 2).




Figure 2: Mouseover for the PubMed "Results by year" timeline tool.

The "PMC images search" tool will display for PubMed search results that meet a number of criteria, e.g., results with a minimum of 250 citations, filters are not active, the search does not include Boolean operators, the search retrieves a minimum of 4 relevant images calculated using a term weighted algorithm.

⊳ b PMC Images search for sars ٠ virus 530 loop s2m Figure 5 SARS Virus RNA Macromolecular Mimicry See more (269)... (A) The SARS s2m RNA structure (red) is superimposed upon the 530 loop of 16S rRNA (cyan), revealing the similar stem-loop folds. Titles with your search terms (B) The IF-1 (magenta) and S12 protein (blue) that bind to the 16S rRNA 530 loop (now hidden) are shown relative to the same s2m RNA Distinct patterns of IFITM-mediated superposition, suggesting that their eukaryotic homologs might plausibly restriction of filoviru [PLoS Pathog. 2011] bind to the s2m RNA. A throat lozenge containing amyl meta cresol a [Antivir Chem Chemother, 2005] The Structure of a Rigorously Conserved RNA Element within the SARS Virus Genome A hexapeptide of the receptor-binding PLoS Biol. PLoS Biol;3(1):e5. domain of SARS co [Antiviral Res. 2012] Lee JM, Kim Y, Chin YW, Jee JG, Keum YS, Jeong YJ. See more Lott 2012 Jun 15:22(12):4040 E4, Epub 2012 Apr 26

To enhance the size of an image, mouseover the thumbnail in the tool (see Figure 3).

Figure 3: Mouseover of an image in the "PMC Images search" tool.

Click within the enhanced image box to display the PubMed Central article for the image.

PubMed Discovery Tools. NLM Technical Bulletin. 2012 May–Jun The PubMed discovery column tools may be modified in the future.

By Kathi Canese National Center for Biotechnology Information

**ISSN 2161-2986 (Online)** Content not copyrighted; freely reproducible. Trademarks Copyright Privacy Accessibility Contact NLM Viewers and Players U.S. National Library of Medicine 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health *NIH...Turning Discovery into Health*® U.S. Department of Health and Human Services Freedom of Information Act

Last updated: 23 April 2013 Permanence level: Permanent: Stable Content



### **MLA 2012: NLM Theater Presentations**

MLA 2012: NLM Theater Presentations. NLM Tech Bull. 2012 May-Jun;(386):e6a.

#### 2012 June 04 [posted]

The NLM exhibit booth at the Annual Meeting of the Medical Library Association featured theater presentations to bring users up-to-date on several NLM products and services.

The presentation recordings are listed below and can also be accessed from the NLM Distance Education Program Resources page.

To listen to the voice recordings and view the captions you may need the latest version of Flash® Player (download for free from the Adobe Web site).

**NLM** Theater Presentations

NLM Online Users' Meeting: PowerPoint Presentations

DOCLINE Users' Group Meeting: PowerPoint Presentation

NLM Update PowerPoint Presentations

NLM Online Users' Meeting: Questions and Answers

Note: To zoom in to detailed screens, use the scroll button.

Presentation with Voice Recording and Captioning	Length (minutes)
Disaster Health Information Update	27:00 min.
Drug, Toxicology & Environmental Health Update	20:00 min.
Everything You Ever Wanted to Know about ClinicalTrials.gov	14:00 min.
LinkOut and Submission Utility Update	8:00 min.
Managing Public Access Compliance Using My NCBI	27:00 min.
MedlinePlus and MedlinePlus Connect	23:00 min.
Native Voices and Other Voices: New from the HMD [no captioning available]	15:00 min.
NIHSeniorHealth Redesign	7:00 min.
Public Health & Health Services Research at NLM: A Tale of Two Portals	17:00 min.
PubMed Health	29:00 min.
PubMed Update	25:00 min.
UMLS and RxNorm Update	20:00 min.

÷

**ISSN 2161-2986 (Online)** Content not copyrighted; freely reproducible. Trademarks Copyright Privacy Accessibility Contact NLM Viewers and Players U.S. National Library of Medicine 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health *NIH...Turning Discovery into Health*® U.S. Department of Health and Human Services Freedom of Information Act

Last updated: 14 February 2014 Permanence level: Permanent: Stable Content



### MLA 2012: NLM Online Users' Meeting: PowerPoint Presentations

MLA 2012: NLM Online Users' Meeting: PowerPoint Presentations. NLM Tech Bull. 2012 May-Jun;(386):e6b.

#### 2012 June 04 [posted]

The NLM Online Users' Meeting, held at the Annual Meeting of the Medical Library Association in Seattle, WA on May 21, 2012, was chaired by David Gillikin, Chief, Bibliographic Services Division, NLM. The meeting brought attendees up-to-date on some of the Library online systems as well as future plans:

- David Gillikin, gave the Online Users' Meeting presentation,
- Loren Frant, Head, Health Information Products Unit, updated users on MedlinePlus, MedlinePlus Connect and NIHSeniorHealth, and
- Janice Kelly, Chief, Outreach & Special Populations Branch, Division of Specialized Information Services (SIS), updated users on a variety of SIS projects and products.

NLM Theater Presentations

NLM Online Users' Meeting: PowerPoint Presentations

DOCLINE Users' Group Meeting: PowerPoint Presentation

NLM Update PowerPoint Presentations

NLM Online Users' Meeting: Questions and Answers

**ISSN 2161-2986 (Online)** Content not copyrighted; freely reproducible. Trademarks Copyright Privacy Accessibility Contact NLM Viewers and Players U.S. National Library of Medicine 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health *NIH...Turning Discovery into Health*® U.S. Department of Health and Human Services Freedom of Information Act

Last updated: 05 September 2012 Permanence level: Permanent: Stable Content



## MLA 2012: DOCLINE Users' Group Meeting: PowerPoint Presentation

MLA 2012: DOCLINE Users' Group Meeting: PowerPoint Presentation. NLM Tech Bull. 2012 May-Jun;(386):e6c.

2012 June 06 [posted]

The DOCLINE Users' Group Meeting was held at the Annual Meeting of the Medical Library Association in Seattle, WA on Sunday, May 20, 2012. Maria Collins of the Public Services Division presented a review of recent and upcoming changes to DOCLINE. Ms. Collins also presented a summary of DOCLINE and Loansome Doc statistics as part of the NLM strategic planning initiative exploring the future of resource sharing. The goal of the initiative is to better understand the resource sharing needs of the National Network of Libraries of Medicine given the declining use of DOCLINE for interlibrary loan and Loansome Doc for document delivery.

The PowerPoint presentation from the meeting is available and includes speaker notes.

**NLM Theater Presentations** 

NLM Online Users' Meeting: PowerPoint Presentations

DOCLINE Users' Group Meeting: PowerPoint Presentation

NLM Update PowerPoint Presentations

NLM Online Users' Meeting: Questions and Answers

**ISSN 2161-2986 (Online)** Content not copyrighted; freely reproducible. Trademarks Copyright Privacy Accessibility Contact NLM Viewers and Players U.S. National Library of Medicine 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health *NIH...Turning Discovery into Health*® U.S. Department of Health and Human Services Freedom of Information Act

Last updated: 01 November 2013 Permanence level: Permanent: Stable Content



### **MLA 2012: NLM Update PowerPoint Presentations**

MLA 2012: NLM Update PowerPoint Presentations. NLM Tech Bull. 2012 May-Jun;(386):e6d.

#### **2012 June 13** [posted]

The NLM Update was held at the Annual Meeting of the Medical Library Association in Seattle, WA on May 22, 2012. There were three speakers at this year's update.

Ms. Betsy Humphreys, Deputy Director, gave an update on NLM-wide projects; Mr. Sheldon Kotzin, Associate Director for Library Operations, gave an update on Library Operations activities as well as selected activities in other NLM Divisions; and Dr. Jeffrey Reznick, Chief, History of Medicine Division, presented on NLM exhibits and History of Medicine programs.

NLM Theater Presentations

NLM Online Users' Meeting: PowerPoint Presentations

DOCLINE Users' Group Meeting: PowerPoint Presentation

NLM Update PowerPoint Presentations

NLM Online Users' Meeting: Questions and Answers

**ISSN 2161-2986 (Online)** Content not copyrighted; freely reproducible. Trademarks Copyright Privacy Accessibility Contact NLM Viewers and Players U.S. National Library of Medicine 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health *NIH...Turning Discovery into Health*® U.S. Department of Health and Human Services Freedom of Information Act

Last updated: 01 November 2013 Permanence level: Permanent: Stable Content

# U.S. NATIONAL LIBRARY OF MEDICINE I NATIONAL INSTITUTES OF HEALTH

#### Table of Contents: 2012 MAY–JUNE No. 386

### MLA 2012: NLM Online Users' Meeting: Questions and Answers

MLA 2012: NLM Online Users' Meeting: Questions and Answers. NLM Tech Bull. 2012 May-Jun;(386):e6e.

### 2012 June 21 [posted]

[Editor's note: Below are the questions and answers from the NLM® Online Users' Meeting at the Annual Meeting of the Medical Library Association in Seattle, WA, May 21, 2012. The answers may have been modified to provide more complete information.] NLM Theater Presentations

NLM Online Users' Meeting: PowerPoint Presentations

DOCLINE Users' Group Meeting: PowerPoint Presentation

NLM Update PowerPoint Presentations

NLM Online Users' Meeting: Questions and Answers

### Question:

Can you talk about your decision to remove the sound from NIH SeniorHealth?

#### Answer:

It was a research decision to remove the audio feature from NIH SeniorHealth. We had a lot of data points that helped us reach this decision; the first is that we saw from our Web analytics that the audio feature was rarely used. When we observed behavior through usability testing, we saw that users tended to turn the audio feature off. So even if we requested that they turn it on, after a certain point they would turn it off because it didn't fit with the experience they wanted to have on the site. The comment that they often gave was, "this is nice for other people, but for me, I don't need this." There are also a lot of screen reader options available that are, in some cases, a better solution because people are very familiar with that tool because they use it across the Web or it just has more advanced features than we are able to offer and maintain. The technical approach that we had for the audio feature doesn't work on some devices and so we would have needed to re-architect it and improve the technology so that it would work across devices. Given the data I just gave you (i.e., feedback, customer use) it just didn't seem like a good investment. But if you're getting feedback from your constituents, we'd love to hear it.

#### Question:

You did a great review of Specialized Information Services (SIS) products. I interact with the environmental health department at the school of public health and it would be helpful if I had a nice presentation to use when I talk to them. Do you have something to offer?

#### Answer:

We don't have any canned presentations, but I'll take that suggestion back to NLM. [Editor's note: For more information on SIS products see Janice Kelly's PowerPoint Presentation from the Sunrise Seminar and listen to the presentations made at the NLM exhibit booth theater.]

#### Question:

I'm interested in the meeting abstracts. Do you have any other mechanism that will be collecting meeting abstracts?

#### Answer:

The decision to discontinue collecting meeting abstracts was made because we can't convert them in a timely manner. For example, we made the 2010 AIDS meeting abstracts available in January 2012 when they were two years old. Our biggest hurdle was converting the content to a format that we can easily put online. In order to process meeting abstracts we started with a print version and scanned it or with a CD ROM that was even more difficult from which to extract the data. Unlike journals, or even books, the conferences and the contractors are not motivated to provide the content in a digital format because they only produce it for their conference.

#### Question:

MLA 2012: NLM Online Users' Meeting: Questions and Answers. NLM Technical Bulletin. 2012 May–Jun

Could you speak to the decision about bringing PubMed Health onboard and how can we help our patrons understand that it's not the same as MedlinePlus?

#### Answer:

PubMed Health focuses on systematic reviews on clinical effectiveness and MedlinePlus is a consumer health resource. They are not intended to overlap. I invite you to come by the booth and attend the PubMed Health presentation at the NLM Theater where Hilda Bastian, one of the main people leading the PubMed Health project, will be giving a presentation and you can get more information from her.

#### Question:

I have a general comment. I really like what you did with PubMed and the filters; they make searching so much easier. The only problem was that the day you implemented it I was teaching. However, the next day I got the new brochures and you did everything so timely so I have to compliment you on that.

Our students are confused when we teach PubMed, PubMed Central, PubMed Health, comparative effectiveness research, other PubMed products. Have you considered creating an integrated or federated search to replace the NLM Gateway that will search all of these products? I was at the SWETS booth and they have a nice piece of software that would help NLM and a lot of our users.

#### Answer:

The PubMed filters are brand new so there may be some tweaks and changes. If you have comments, please send them to us through the Write to the Help Desk link on any PubMed page. We appreciate your feedback and watch for trends through the comments you send us. This information helps us to improve our products.

Yes, the Gateway is gone and it did integrate resources, but quite frankly, few people used it. Federated searching across similar databases works well, but the key is to have similar data types. The Gateway transformed to a pilot project because the usage was very minimal and continued to decrease. We will take your comment back about integrated approaches to some of the databases. *[Editor's Note: NCBI offers a federated-like search page for the NCBI databases called the Entrez cross-database search page.]* 

ISSN 2161-2986 (Online) Content not copyrighted; freely reproducible.

Trademarks Copyright Privacy Accessibility Contact NLM Viewers and Players

U.S. National Library of Medicine 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health *NIH...Turning Discovery into Health*® U.S. Department of Health and Human Services Freedom of Information Act Last updated: 14 February 2014 Permanence level: Permanent: Stable Content



### New Look, New Collections for IndexCat Database

DuQuette, LA. New Look, New Collections for IndexCat Database. NLM Tech Bull. 2012 May-Jun;(386):e5.

#### 2012 May 22 [posted]

The History of Medicine Division (HMD) of the National Library of Medicine (NLM) announces the launch of a new user interface for its premier database, IndexCat, along with the addition of two new collections involving medieval scientific English and Latin texts.

Utilizing software developed by Ex Libris, Inc., the new IndexCat interface offers improved viewing capabilities and new layouts for search results and record displays. IndexCat is available free of charge.


#### New Homepage

IndexCat has a new homepage with these major sections (see Figure 1):

- About
  - Index-Catalogue
  - IndexCat Database
    - eTK/eVK2 Collection
  - Project Histories
    - IndexCat
    - eTK/eVK2

• FAQs (Frequently Asked Questions)

A **SEARCH** button at the top right corner takes you to the IndexCat Database Search page. The page also links to other HMD and NLM resources.



#### **New Collections**

The two new collections are an NLM-supported project undertaken in conjunction with the University of Missouri-Kansas City. These seminal, historical collections are developed from the enriched electronic database of *A Catalogue of Incipits of Mediaeval Scientific Writings in Latin* (rev.) by Lynn Thorndike and Pearl Kibre (eTK) and the updated and expanded version of *Scientific Writings in Old and Middle English: An Electronic Reference* (eVK2) edited by Linda Ehrsam Voigts and Patricia Deery Kurtz (see Figure 2). Opening a new frontier in historical research, these resources encompass over 42,000 records of incipits, or the beginning words of a medieval manuscript or early printed book. IndexCat users can search incipit data by manuscript, library, author/translator, title, subject, date and other information. See eTK/eVK2 Project for more information.

NATIONAL LIBRARY OF MEDICINE	Search My Documents Co	omments Help	Exit
Quick Search	Advanced Search IndexCat New Features Special Characters for eTK/eVK2		
Search for:	within Keyword Anywhere (automatic AND)		
Collections:	Click the 🗈 icon to browse specific collection(s)    Electronic Thorndike and Kibre (eTK for medieval Latin texts); 2 i  Electronic Voigts and Kurtz (eVK2 for medieval English texts); 2 i  Electronic Voigts and Kurtz (eVK2 for medieval English texts); 2 i  Library Catalogue of the Library of the Surgeon-General's Office i  Library Catalog - LocatorPlus i  Search		

#### Figure 2: Collections on Quick Search Page.

#### **Search Page Changes**

**Quick Search Tab** There now are additional search categories on the Quick Search tab (see Figure 3):

- Keyword Anywhere (automatic AND)
- Keyword Anywhere Search
- Author Search
- Date Search
- ID Number Search
- Item Type Search (Index-Catalogue only)
- Language Search (eVK2 only)
- Subject Search
- Title/Journal Title Search

The same categories are also offered on the Advanced Search tab.

	Search My Documents Comments Help Exit
Quick Search Advanced Search IndexCat New Features Search for: within	Special Characters for eTK/eVK2 Keyword Anywhere (automatic AND) Keyword Anywhere (automatic AND) Keyword Anywhere Search
Collections: Click the  i con to browse specific collection(s)    Electronic Thorndike and Kibre (eTK for medieval Latin te  Electronic Voigts and Kurtz (eVK2 for medieval English te  Electronic Voigts and Kurtz (eVK2 for medieval English te  Library Catalogue of the Library of the Surgeon-General's ( Library Catalog - LocatorPlus  Search	Author Search Date Search × ID Number Search × Item Type Search (Index-Catalogue only)

Figure 3: Search Category Options on Quick Search.

New Look, New Collections for IndexCat Database. NLM Technical Bulletin. 2012 May-Jun

#### My Documents Tab

You now have the ability to select multiple records from the Results Display page after a search to save to the My Documents page (see Figure 4).

You can save a maximum of 100 records to the My Documents page.

Using the My Documents page, you can select multiple items to print, download, or e-mail.

The My Documents records list is cumulative up to 100 records unless you remove items. You can add records from different searches during the same IndexCat access session. IndexCat does not retain your saved records if you exit or disconnect.

LIBRA	NATIONAL LEBRARYOF MEDICINE	
	Search My Documents Comments Help Exit	_
	results summary results display search histo	iry
You h	ou have 4 saved documents. Click the checkboxes to save, email, print or remove records.	
	O NOT click on Record Details as an error will occur and you will need to restart your search.	
The list of	list of all saved documents on this page will be deleted once you terminate your IndexCat session.	
C	Remove Email Print Save ASCII Save RIS Check Page Uncheck Page	
	1. 30105671470 Krzyszkowski, J. (Patho-anatomy of carbuncle.) 1901.	
	Collection: Index-Catalogue Series 3	
	Record Details	
-		
	Collection: Index-Catalogue Series 3	
	Record Details	
	3. 30105701340 Thompson, L. L. The etiology and treatment of carbuncle or benign anthrax. 1901.	
	Collection: IndexoCatalogue Series 3	
	Record Details	
	4. 30105701430 West, R. M. The local treatment of carbuncle, 1896.	
	Collection: Index-Catalogue Series 3	
	Record Details	
	Remove Email Print Save ASCII Save RIS Check Page Uncheck Page	

Figure 4: My Documents Page.

#### Special Characters for eTK/eVK2

The [link removed] Special Characters for eTK/eVK2 page provides assistance with searching for terms that contain special characters in the eTK/eVK2 collections.

#### **Index-Catalogue Corrections**

Corrections made to the Index-Catalogue records include:

- edits to punctuation
- corrections to 'See Also' in Subject fields
- the addition of daggers to identify Cases/Case Reports in Series 1, [Case Reports] to the Title field in Series 1, and asterisks to identify dissertations in Series 2.

#### **New FAQs and Help Pages**

There are a number of new and revised FAQs and [link removed] Help pages for IndexCat.

We welcome your feedback via the [link removed] Comments tab at the top of every page.

New Look, New Collections for IndexCat Database. NLM Technical Bulletin. 2012 May–Jun

**ISSN 2161-2986 (Online)** Content not copyrighted; freely reproducible. Trademarks Copyright Privacy Accessibility Contact NLM Viewers and Players U.S. National Library of Medicine 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health *NIH...Turning Discovery into Health*® U.S. Department of Health and Human Services Freedom of Information Act

Last updated: 14 February 2014 Permanence level: Permanent: Stable Content



### UMLS 2012AA Release Available

Wilder V. UMLS 2012AA Release Available. NLM Tech Bull. 2012 May-Jun;(386):e4.

**2012 May 07** [posted]

#### UMLS 2012AA Release Available

The 2012AA release of the Unified Medical Language System (UMLS) Knowledge Sources is available as of May 7, 2012 from the *Downloads* menu of the UMLS Terminology Services (UTS).

In the new UMLS Release there are:

- More than 2.7 million concepts and 10.8 million unique concept names from over 160 source vocabularies; the full Metathesaurus requires 23 GB of disk space
- Three new sources
  - US Extension to SNOMED CT (SCTUSX)
  - Quality of Life Outcomes in Neurological Disorders (LNC\_NEUROQOL)
  - Outpatient Physical Therapy Improvement in Movement Assessment Log (LNC\_OPTIMAL)
- One new translation
  - Norwegian translation of the Medical Subject Headings (MSHNOR)
- 38 updated English sources and 20 updated translation sources including MedlinePlus Health Topics, MeSH, MedDRA, RxNorm, and SNOMED CT (English and Spanish)
- SPECIALIST Lexicon and Lexical Tools 2012 Releases

#### **Data Changes**

- The maximum length for the attribute name (ATN) field in the MRSAT file is now 100 characters. The database load scripts produced by MetamorphoSys reflect this change.
- Two source name changes appear in MRSAB. Their Metathesaurus source abbreviations (SAB) remain the same.
  - National Drug Data File Plus Vocabulary (SAB=NDDF) is now FDB MedKnowledge (formerly NDDF Plus).
    - Gold Standard Alchemy (SAB=GS) is now Gold Standard Drug Database.

#### **Clinical Care Classification**

• Clinical Care Classification (CCC) is the update of the former Home Health Classification (HHC). The 2003 version of HHC remains as one of the 2012AA Metathesaurus vocabulary sources. HHC will be removed from the Metathesaurus in 2012AB.

#### **US Extension to SNOMED CT**

• The Metathesaurus includes the March 1 version of the US Extension to SNOMED CT.

#### **Release Information**

For more information about the release, see the What's New and Updated Sources sections of the Release Documentation. Additional release statistics are published on the UMLS Web site.

To access the UMLS Release files, you must have an active UMLS Metathesaurus License and a valid UTS account. You will be prompted for your UTS username and password when downloading the files.

Additional information regarding the UMLS is available on the UMLS homepage. New users are encouraged to take the UMLS Basics Tutorial and to explore the new UMLS Quick Start Guide, training materials and other information on the New Users' homepage.

#### DVDs

As always, the production and mailing of the UMLS DVDs occur about four weeks after the release is made available for download.

To request or cancel a DVD: Sign in to the UTS and edit your UTS profile to select or deselect the DVD option.

**Source Release Documentation** 2012AA Source Release Documentation Web pages will be published following the release.

By Victoria Wilder MEDLARS Management Section

ISSN 2161-2986 (Online) Content not copyrighted; freely reproducible.

Trademarks Copyright Privacy Accessibility Contact NLM Viewers and Players U.S. National Library of Medicine 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health NIH ... Turning Discovery into Health® U.S. Department of Health and Human Services Freedom of Information Act

Last updated: 01 November 2013 Permanence level: Permanent: Stable Content



### **PubMed Filters Sidebar Replaces the Limits Page**

Canese K. PubMed Filters Sidebar Replaces the Limits Page. NLM Tech Bull. 2012 May-Jun; (386):e3.

2012 May 02 [posted] 2012 May 10 [Editor's note added] 2012 May 15 [Editor's note added]

[Editor's note: These changes were implemented in PubMed on May 10, 2012.] [Editor's note: The PubMed Tutorial has been updated to reflect this recent change. Also, see the Filters Sidebar tutorial on YouTube on May 15, 2012.]

In order to provide users with a more visible and accessible way to narrow PubMed results, the Limits page will be replaced by a results filter sidebar. The filter sidebar options will work the same way as the limit selections; that is, once a filter is selected it will be activated for subsequent searches until the selection is cleared (see Figure 1).

SNCBI Resources	☑ How To ☑
Publiced.gov US National Library of Medicine National Institutes of Health	PubMed Cystic fibrosis
Choose additional filters	Display Settings: Summary, 20 per page, Sorted by Recently Added Send to:
Text availability	Results: 1 to 20 of 36058         << First         < Prev         Page 1         of 1803         Next >         Last >>
Abstract available	The military importance of cystic fibrosis.
Free full text available	1. Dickinson JG.
Full text available	J R Army Med Corps. 2012 Mar;158(1):67; author reply 67. No abstract available.
Publication	PMID: 22545380 [PubMed - in process]
dates	
5 years	Functional analysis of non-synonymous single nucleotide polymorphisms in human
10 years	2. <u>SLC26A9.</u>
Custom range	Chen AP, Chang MH, Romero MF. Hum Mutat. 2012 Apr 27. doi: 10.1002/humu.22107. [Epub ahead of print]
Species	PMID: 22544634 [PubMed - as supplied by publisher]
Humans	Related citations
Other Animals	
Other Pullindis	Quantitative Ultrasound in Spanish Children and Young Adults With Cystic Fibrosis.
Article types	3. Lopez-Rodriguez MJ, Lavado-Garcia JM, Canal-Macias ML, Calderon-Garcia JF,
Clinical Trial	Moran JM, Pedrera-Zamorano JD.
Meta-Analysis	Biol Res Nurs. 2012 Apr 28. [Epub ahead of print]
Practice Guideline	PMID: 22544518 [PubMed - as supplied by publisher]
Randomized Controlled Trial	Related citations
Review	A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite
Systematic Reviews	4. stimulation in cystic fibrosis.
more	Epifanio M, Marostica P, Mattiello R, Feix L, Nejedlo R, Fischer G, Stein R.
Languages	J Pediatr (Rio J). 2012 Mar;88(2):155-60.
English	PMID: 22544046 [PubMed - in process] Free Article
more	Related citations
	Airway epithelial cells-Hyperabsorption in CF?
Clear all	
	Kunzeimann K, Schreiber K.
Choose additional filters	Int J Biochem Cell Biol. 2012 Apr 21. [Epub ahead of print] PMID: 22542896 [PubMed - as supplied by publisher]
	Figure 1: PubMed results with default filter sidebar ontions

Figure 1: PubMed results with default filter sidebar options.

Click a filter to narrow your search results, e.g., you may filter your search results for cystic fibrosis to Clinical Trial and articles published in the last 10 years. A "Filters activated" message will display on the result page (see Figure 2).

S NCBI Resources 🗹 How To 🗹			
Publed.gov US National Library of Medicine National Institutes of Health	PubMed <ul> <li>cystic fibrosis</li> <li>RSS Save search Advanced</li> </ul>		
<u>Choose additional</u> filters	Display Settings:  Summary, 20 per page, Sorted by Recently Added		
Clear all	<u>Send to:</u> ⊘		
<u>Clear all</u>	Results: 1 to 20 of 704 << First < Prev Page 1 of 36 Next > Last >>		
Text availability	Filters activated: published in the last 10 years, Clinical Trial <u>Clear all</u>		
Abstract available Free full text available Full text available	<ul> <li>Adults with cystic fibrosis prefer hypertonic saline before or during</li> <li>airway clearance techniques: a randomised crossover trial.</li> <li>Dentice RL, Elkins MR, Bye PT.</li> </ul>		
Publication clear dates 5 years	J Physiother. 2012;58(1):33-40. PMID: 22341380 [PubMed - indexed for MEDLINE] <u>Related citations</u>		
✓ 10 years Custom range	<ul> <li>[Analytical quality of assays and comparison of procedures for the sweat</li> <li>test].</li> </ul>		
<b>Species</b> Humans Other Animals	Nguyen-Khoa T, Borgard JP, Marchand M, Sitruk-Khalfon D, Feuillet MN, Feldmann D, Vassault A, Rota M. Ann Biol Clin (Paris). 2012 Jan-Feb;70(1):5-12. French. PMID: 22294136 [PubMed - indexed for MEDLINE]		
Article types clear	Related citations		
✓ Clinical Trial Randomized Controlled Trial Review	<ul> <li>Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with</li> <li>pseudomonas airway infection.</li> <li>Trapnell BC, McColley SA, Kissner DG, Rolfe MW, Rosen JM, McKevitt</li> </ul>		
Systematic Reviews more Languages	M, Moorehead L, Montgomery AB, Geller DE; Phase 2 FTI Study Group. Am J Respir Crit Care Med. 2012 Jan 15;185(2):171-8. Epub 2011 Nov 17. PMID: 22095545 [PubMed - indexed for MEDLINE] Related citations		
English			
more	Timing of dornase alpha inhalation does not affect the efficacy of an		

## Figure 2: PubMed cystic fibrosis results filtered by the last 10 years publication date and Clinical Trial.

Only valid filter options for a result set will display on the sidebar, e.g., Meta-Analysis was removed from the filter list in the search above because none of the result citations were tagged with that article type.

To turn off filters, click either the "Clear all" link to remove all the filters, the "clear" link next to a filter category to clear the selections within that category, or the individual filter.

To add additional filter categories to the sidebar, click the "Choose additional filters" link, select the additional categories, and then click Apply (see Figure 3).

S NCBI Resources	🗵 How To 🗹	
Public gov US National Library of Medicine National Institutes of Health	PubMed cystic fib	orosis Save search Advanced
Choose additional filters Text availability Abstract available Free full text available Full text available Full text available Full text available Full text available Full text available Syears 10 years Custom range Species Humans Other Animals Article types Clinical Trial	<ul> <li>Choose additional filters</li> <li>Text availability</li> <li>Publication dates</li> <li>Species</li> <li>Article types</li> <li>Article types</li> <li>Languages</li> <li>Sex</li> <li>Subjects</li> <li>Journal categories</li> <li>Ages</li> <li>Search fields</li> </ul>	20 per page, Sorted by Recently Added Send to: <pre></pre>

## Figure 3: Filters sidebar "Choose additional filters" pop-up selection box with Sex and Ages selected.

To add filters to the sidebar for categories with many selections, click the category "more ..." link, select the additional filters, and then click Apply (see Figure 4).

Article types Clinical Trial	Languages	×	1
Meta-Analysis	🗆 Afrikaans	<b></b>	ay epithelial wound repair after
Practice Guideline	🗖 Albanian		
Randomized	C Arabic		D, Lingée S, Ferraro P,
Controlled Trial	□ Armenian		
Review	🗆 Azerbaijani		
Systematic Reviews			1
more			
Languages	□ Bulgarian		uginosa in patients with cystic
English	🗖 Catalan		aginosa in patento war ojsto
French	Chinese		1. Rowe SM.
more	Croatian		543. [Epub ahead of print]
	Czech		1
Ages	Danish		
Infant: birth-23 months	Dutch		
	English		nary guidelines: A national
Child: 0-18 years Adult: 19+ years			
Adult: 19-44 years	Esperanto		asulnia M, Salinas GD, Zhang
Aged: 65+ years	Estonian		
more	Finnish		02/ppul.21573. Epub 2012 Jan 3.
11016	French	•	
Sex	—		
Male			allbladder and amniotic fluid
Female	Apply		
		,	A, Rival JM, de Becdelievre A,

#### Figure 4: Filters sidebar category "more ..." pop-up selection box with languages selected.

The PubMed default Review and Free full text filters have been moved to the filters sidebar. The "Filter your results" portlet will eventually be incorporated into the filters sidebar.

By Kathi Canese National Center for Biotechnology Information

ISSN 2161-2986 (Online) Content not copyrighted; freely reproducible.

Trademarks Copyright Privacy Accessibility Contact NLM Viewers and Players U.S. National Library of Medicine 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health *NIH...Turning Discovery into Health*® U.S. Department of Health and Human Services Freedom of Information Act

Last updated: 11 April 2013 Permanence level: Permanent: Stable Content



### **PubMed and Computed Author Sorted Display**

Canese K. PubMed and Computed Author Sorted Display NLM Tech Bull. 2012 May-Jun; (386):e2.

2012 May 02 [posted] 2012 May 10 [Editor's note added] 2013 November 25 [Figure replaced]

[Editor's note: These changes were implemented in PubMed on May 10, 2012.]

The PubMed Abstract display will soon be modified to display results using a ranking algorithm when users click the author search link. Because an author may share the same name with other authors, the objective is to display more relevant results by disambiguating common author names.

When users click the author name link on the abstract display (see Figure 1), an author search is executed in PubMed.

Biochim Biophys Acta. 2012 May;1822(5):690-713. Epub 2011 Dec 28.

### Oxidative stress and antioxidant therapy in cystic fibrosis.

Galli F, Battistoni A, Gambari R, Pompella A, Bragonzi A, Pilolli F, Iuliano L, Piroddi M, Dechecchi MC, Cabrini G. Department of Internal Medicine, Laboratory of Clinical Biochemistry and Nutrition, University of Perugia, Italy.

#### Abstract

Cystic fibrosis is a lethal autosomal recessive condition caused by a defect of the transmembrane conductance regulator gene that has a key role in cell homeostasis. A dysfunctional cystic fibrosis transmembrane conductance regulator impairs the efflux of cell anions such as chloride and bicarbonate, and also that of other solutes such as reduced glutathione. This defect produces an increased viscosity of secretions together with other metabolic defects of epithelia that ultimately promote the obstruction and fibrosis of organs. Recurrent pulmonary infections and respiratory dysfunction are main clinical consequences of these pathogenetic events, followed by pancreatic and liver insufficiency, diabetes, protein-energy malnutrition, etc. This complex comorbidity is associated with the extensive injury of different biomolecular targets by reactive oxygen species, which is the biochemical hallmark of oxidative stress. These biological lesions are particularly pronounced in the lung, in which the extent of oxidative markers parallels that of inflammatory markers between chronic events and acute exacerbations along the progression of the disease. Herein, an abnormal flux of reactive oxygen species is present by the sustained activation of neutrophils and other cystic fibrosis-derived defects in the homeostatic processes of pulmonary epithelia and lining fluids. A sub-optimal antioxidant protection is believed to represent a main contributor to oxidative stress and to the poor control of immuno-inflammatory pathways in these patients. Observed defects include an impaired reduced glutathione metabolism and lowered intake and absorption of fat-soluble antioxidants (vitamin E, carotenoids, coenzyme Q-10, some polyunsaturated fatty acids, etc.) and oligoelements (such as Se, Cu and Zn) that are involved in reactive oxygen species detoxification by means of enzymatic defenses. Oral supplements and aerosolized formulations of thiols have been used in the antioxidant therapy of this inherited disease with the main aim of reducing the extent of oxidative lesions and the rate of lung deterioration. Despite positive effects on laboratory end points, poor evidence was obtained on the side of clinical outcome so far. These aspects examined in this critical review of the literature clearly suggest that further and more rigorous trials are needed together with new generations of pharmacological tools to a more effective antioxidant and antiinflammatory therapy of cystic fibrosis patients. This article is part of a Special Issue entitled: Antioxidants and Antioxidant Treatment in Disease.

#### Figure 1: PubMed abstract display with author name links.

If an author name is computationally similar to an author name for additional PubMed citations, the results will display those citations first, in ranked order, followed by the non-similar citations. The results sort notation will display as "Sorted by Computed Author" (see Figure 2).

[Editor's Note: Figure 2 was replaced on November 25, 2013.]

US Na	Dimed.gov     PubMed     Cabrini G[Author]       ational Library of Medicine     Advanced
Disp	<u>blay Settings:</u> Summary, 200 per page, Sorted by Computed Author <u>Send to:</u> Send to:  Send t
Res	sults: 127
<b>1</b> .	Oxidative stress and antioxidant therapy in cystic fibrosis. Galli F, Battistoni A, Gambari R, Pompella A, Bragonzi A, Pilolli F, Iuliano L, Piroddi M, Dechecchi MC, Cabrini G; Working Group on Inflammation in Cystic Fibrosis. Biochim Biophys Acta. 2012 May;1822(5):690-713. doi: 10.1016/j.bbadis.2011.12.012. Epub 2011 Dec 28. Review. PMID: 22226887 [PubMed - indexed for MEDLINE] Related citations
2.	Chloride conductance in membrane vesicles from human placenta using a fluorescent probe. Implications for cystic fibrosis. Dechecchi MC, Cabrini G. Biochim Biophys Acta. 1988 Nov 22;945(2):113-20. PMID: 3191115 [PubMed - indexed for MEDLINE] Related citations
3.	Targeting transcription factor activity as a strategy to inhibit pro-inflammatory genes involved in cystic fibrosis: decoy oligonucleotides and low-molecular weight compounds. Cabrini G, Bezzerri V, Mancini I, Nicolis E, Dechecchi MC, Tamanini A, Lampronti I, Piccagli L, Bianchi N, Borgatti M, Gambari R. Curr Med Chem. 2010;17(35):4392-404. Review. PMID: 20939807 [PubMed - indexed for MEDLINE] Related citations
4.	Decoy oligodeoxyribonucleotides and peptide nucleic acids-DNA chimeras targeting nuclear factor kappa-B: inhibition of IL-8 gene expression in cystic fibrosis cells infected with Pseudomonas aeruginosa. Gambari R, Borgatti M, Bezzerri V, Nicolis E, Lampronti I, Dechecchi MC, Mancini I, Tamanini A, Cabrini G. Biochem Pharmacol. 2010 Dec 15;80(12):1887-94. doi: 10.1016/j.bcp.2010.06.047. Epub 2010 Jul 6. Review. PMID: 20615393 [PubMed - indexed for MEDLINE] Related citations

### Figure 2: PubMed Abstract author link search results for Cabrini G. Sorted by Computed Author.

The author name disambiguation process compares citations with the same author name. The similarity for each citation pair is measured by examining the metadata for both citations, such as co-authors, journal, title, affiliation, abstract, MeSH terms, grants, and publication date. Citations that share like author names are divided into different groups by clustering the citations that are highly similar to each other. Citations within each group are then classified as belonging to the same author. When a PubMed Abstract display author name link is clicked, the citations computed as belonging to that same author are displayed in the order of similarity to that citation.

Previously, an author name search executed from the abstract display was enclosed in double quotes; however, the updated author search will no longer include double quotes.

If an author name is not computationally similar to other PubMed citations, the results for the author search will display in the default sort order recently added. In addition, author searches entered in the PubMed search box will continue to display in the default sort order.

By Kathi Canese National Center for Biotechnology Information

ISSN 2161-2986 (Online) Content not copyrighted; freely reproducible.

Trademarks Copyright Privacy Accessibility Contact NLM Viewers and Players U.S. National Library of Medicine 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health *NIH...Turning Discovery into Health*® U.S. Department of Health and Human Services Freedom of Information Act

Last updated: 28 October 2013 Permanence level: Permanent: Stable Content



### **NLM Classification 2012 Edition Now Available**

Willis, SR. NLM Classification 2012 Edition Now Available. NLM Tech Bull. 2012 May-Jun; (386):e1.

#### 2012 May 01 [posted]

The *NLM Classification*, available online at http://www.nlm.nih.gov/class, incorporates all additions and changes to the schedules and index from April 2011 through March 2012. The PDF version will be updated with 2012 classification data by the end of May 2012.

The QV (Pharmacology) schedule was the major area of focus for the 2012 edition.

Some QV schedule outline headers were changed.

For example:

- QV 610-618 Inorganic Poisons was changed to QV 610-666 Poisons
- QV 627-633 Organic Poisons and QV 662-667 Gas Poisons. Chemical Agents were deleted

Some QV class number captions and notes were revised to better reflect the scope of the number. For example:

- At QV 38, the caption Drug action was changed to Drug metabolism. Pharmacokinetics.
- At QV 95, the caption Anti-inflammatory analgesics was changed to Non-steroidal anti-inflammatory agents.
- Disinfectants was removed from the caption at QV 220 and added to the caption at QV 250.
- At QV 240, the caption *Dyes and related compounds used in diagnosis or as reagents, indicators, etc.* was changed to *Coloring agents*.
- At QV 241, the caption Tars. Balsams was changed to Complex mixtures.
- At QV 310, the caption Gases and their compounds was changed to Noble gases.
- At QV 663, the caption *Chemical agents* was augmented with *Chemical warfare agents*.
- At QV 772, the caption Non-prescription drugs was changed to Drug catalogs.
- At QV 778, the caption *Pharmaceutical processes. Drug compounding* was changed to *Drug delivery* systems (General or not elsewhere classified).
- At QV 785, the caption *Types of pharmaceutical preparations*. *Dosage forms* was changed to *Drug delivery systems*.
- At QV 786, the caption *Solutions* was changed to *Drug dosage forms (General or not elsewhere classified)*.
- At QV 800, the caption *Vehicles* was changed to *Pharmaceutic aids*.
- At QV 4, the note was added: Classify here works discussing both pharmacological phenomena and pharmaceutical preparations. Classify works on pharmacological phenomena only in QV 37.
- At QV 55, the note was added: Classify here general works on pharmaceutical preparations and works on specific drugs not elsewhere classified.

Table G (geographic breakdown) is now permitted with QV 736 and QV 737.

#### **Class Numbers Added and Canceled**

Thirty-seven (37) new class numbers were added and four (4) class numbers were canceled.

Class Numbers Added – 2012

New Number Class Name

Former Number in the Index

QV 786.5.05OintmentsQV 785QV 786.5.P7PowdersQV 785, etcQV 786.5.S6SolutionsQV 786QV 786.5.S8SuppositoriesQV 785, etcQV 786.5.T3TabletsQV 787WA 290Emergency respondersNoneWA 320.1[Child welfare. Child health services] General coverage (Not Table G)WA 320WA 346CutaneousWB 340WA 510Trigger pointsWE 550	Canceled Nun	nber Class Name Now	Classed in
QV 36Receptor pharmacologyQV 38QV 37.Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 37.5Biotransformation. PharmacogeneticsQV 72QV 57Nonprescription drugsQV 72QV 151Antihypertensive agents. Calcium channel blockersQV 150QV 604Lists of poisons, antidotes, etc.QV 603QV 633.5Specific hydrocarbons, A-ZQV 633QV 633.5.45Benzene. Benzene derivativesQV 633QV 633.5.41Halogenated hydrocarbonsQV 633QV 736.11[Drug industry. Economics of pharmacy. Advertising] General coverage (Not Table G)QV 736QV 737.11[Drug industry. Economics of pharmacy. Pharmacies] coverage (Not Table G)QV 736QV 745Drug design. Drug discoveryQV 744QV 771.4Clinical trialsQV 736QV 785.5Special dosage forms, A-ZQV 785QV 786.5.65SolutionsQV 785QV 786.5.77ColloidsQV 736QV 785.5Special dosage forms, A-ZQV 785QV 786.5.75SolutionsQV 785QV 786.5.76SolutionsQV 785QV 786.5.77ColloidsQV 785QV 786.5.78SuppositoriesQV 785QV 786.5.79PowdersQV 785QV 786.5.74GutaneousQV 785QV 786.5.75SolutionsQV 785QV 786.5.76SuppositoriesQV 785QV 786.5.77Child welfare. Child health services] General cover	Class Numbers	s Canceled — 2012	
QV 36Receptor pharmacologyQV 38QV 37.Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 37.5Biotransformation. PharmacogeneticsQV 72QV 57Nonprescription drugsQV 72QV 151Antihypertensive agents. Calcium channel blockersQV 150QV 604Lists of poisons, antidotes, etc.QV 603QV 633.5Specific hydrocarbons, A-ZQV 633QV 633.5.45Benzene. Benzene derivativesQV 633QV 633.5.41Halogenated hydrocarbonsQV 633QV 736.11[Drug industry. Economics of pharmacy. Advertising] General coverage (Not Table G)QV 736QV 737.11[Drug industry. Economics of pharmacy. Pharmacies] coverage (Not Table G)QV 736QV 745Drug design. Drug discoveryQV 744QV 771.4Clinical trialsQV 736QV 785.5Special dosage forms, A-ZQV 785QV 786.5.65SolutionsQV 785QV 786.5.77ColloidsQV 736QV 785.5Special dosage forms, A-ZQV 785QV 786.5.75SolutionsQV 785QV 786.5.76SolutionsQV 785QV 786.5.77ColloidsQV 785QV 786.5.78SuppositoriesQV 785QV 786.5.79PowdersQV 785QV 786.5.74GutaneousQV 785QV 786.5.75SolutionsQV 785QV 786.5.76SuppositoriesQV 785QV 786.5.77Child welfare. Child health services] General cover	WQ 270	Maternal death	None
QV 36Receptor pharmacologyQV 38QV 37.Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 37.5Biotransformation. PharmacogeneticsQV 72QV 57Nonprescription drugsQV 72QV 151Antihypertensive agents. Calcium channel blockersQV 150QV 604Lists of poisons, antidotes, etc.QV 633QV 633.5Specific hydrocarbons, A-ZQV 633QV 633.5Fossil fuelsQV 633QV 633.5.13Halogenated hydrocarbonsQV 633QV 736.1Ibrug industry. Economics of pharmacy. Advertising] General coverage (Not Table G)QV 736QV 745Drug design. Drug discoveryQV 744QV 745Special dosage forms, A-ZQV 736QV 745Special dosage forms, A-ZQV 736QV 745CapualoutingQV 736QV 736.1[Drug industry. Economics of pharmacy. Advertising] General coverage (Not Table G)QV 736QV 745Drug design. Drug discoveryQV 744QV 745Special dosage forms, A-ZQV 785QV 786.5C7ColloidsQV 785QV 786.5C7ColloidsQV 785QV 786.5C8Special dosage forms, A-ZQV 785QV 786.5C9Special dosage forms, A-ZQV 785QV 786.5C7ColloidsQV 785QV 786.5C8SpuestoresQV 785QV 786.5C9SpuestoresQV 785QV 786.5C9SpuestoresQV 785QV 786.5C9SpuestoresQV 785 <td>-</td> <td></td> <td>-</td>	-		-
QV 36Receptor pharmacologyQV 38QV 37Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 37.5Biotransformation. PharmacogeneticsQV 72QV 57Nonprescription drugsQV 772QV 151Antihypertensive agents. Calcium channel blockersQV 603QV 604Lists of poisons, antidotes, etc.QV 603QV 633.5Specific hydrocarbons, A-ZQV 633QV 633.5Benzene. Benzene derivativesQV 633QV 633.5Halogenated hydrocarbonsQV 633QV 633.5Halogenated hydrocarbonsQV 633QV 736.1[Drug industry. Economics of pharmacy. Advertising] General coverage (Not Table G)QV 736QV 737.1[Pharmaceutical services. Community pharmacy. Pharmacies] General coverage (Not Table G)QV 737QV 745Drug design. Drug discoveryQV 744QV 771.4Clinical trialsQV 785QV 786.5Special dosage forms, A-ZQV 785QV 786.5Gapuelse forms, A-ZQV 785QV 786.5Caloudse forms, A-ZQV 785QV 771.4Clinical trialsQV 771QV 775Drug compoundingQV 785QV 786.5Special dosage forms, A-ZQV 785QV 786.5SolutionsQV 785QV 786.5.05OintmentsQV 785QV 786.5.05SolutionsQV 785QV 786.5.05SolutionsQV 785QV 786.5.05SolutionsQV 785QV 786.5.05SolutionsQV			
QV 36Receptor pharmacologyQV 38QV 37Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 37.5Biotransformation. PharmacogeneticsQV 38QV 57Nonprescription drugsQV 150QV 151Antihypertensive agents. Calcium channel blockersQV 605QV 604Lists of poisons, antidotes, etc.QV 603QV 633.5Specific hydrocarbons, A-ZQV 633QV 633.5.H4Benzene. Benzene derivativesQV 633QV 633.5.H5Fossil fuelsQV 633QV 736.1[Drug industry. Economics of pharmacy. Advertising] General coverage (Not Table G)QV 736QV 737.1[Pharmaceutical services. Community pharmacy. Pharmacies] General coverage (Not Table G)QV 737QV 745Drug design. Drug discoveryQV 738QV 785.5Special dosage forms, A-ZQV 738QV 786.5Special dosage forms, A-ZQV 738QV 779Drug compoundingQV 774QV 779Drug compoundingQV 738QV 786.5GolitonsQV 785QV 786.5.7ColloidsQV 785QV 786.5.71FowdersQV 785QV 786.5.72SolutionsQV 785QV 786.5.73TabletsQV 785QV 786.5.74SoupositoriesQV 785QV 786.5.75SolutionsQV 785QV 786.5.74SolutionsQV 785QV 786.5.75SolutionsQV 785QV 786.5.74SolutionsQV 785QV 786.5.75<		-	
QV 36Receptor pharmacologyQV 38QV 37Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 38.5Biotransformation. PharmacogeneticsQV 38QV 57Nonprescription drugsQV 772QV 151Antihypertensive agents. Calcium channel blockersQV 605QV 604Lists of poisons, antidotes, etc.QV 605QV 633.5Specific hydrocarbons, A-ZQV 633QV 533.5.84Benzene. Benzene derivativesQV 633QV 633.5.84Benzene. Benzene derivativesQV 633QV 633.5.84Halogenated hydrocarbonsQV 633QV 736.1[Drug industry. Economics of pharmacy. Advertising] General coverage (Not Table G)QV 771QV 772.4Clinical trialsQV 771QV 774.5Drug design. Drug discoveryQV 778QV 785.5Special dosage forms, A-ZQV 785QV 786.5.6Special dosage forms, A-ZQV 785QV 786.5.7ColloidsQV 772QV 772.4Clinical trialsQV 771QV 775.5Special dosage forms, A-ZQV 785QV 786.5.7ColloidsQV 785QV 786.5.65SolutionsQV 785QV 786.5.71TablesQV 785QV 786.5.72ColloidsQV 785QV 786.5.73TablesQV 785QV 786.5.74OversaQV 785QV 786.5.75SolutionsQV 785QV 786.5.76SolutionsQV 785QV 786.5.78SuppositoriesQV 785 </td <td></td> <td></td> <td></td>			
QV 36Receptor pharmacologyQV 38QV 37Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 38.5Biotransformation. PharmacogeneticsQV 38QV 57Nonprescription drugsQV 772QV 151Antihypertensive agents. Calcium channel blockersQV 150QV 633Specific hydrocarbons, ArZQV 633QV 633.5Specific hydrocarbons, ArZQV 633QV 633.5.B4Benzene. Benzene derivativesQV 633QV 633.5.B4Halogenated hydrocarbonsQV 633QV 633.5.B4Ibagenated hydrocarbonsQV 633QV 736.1[Drug industry. Economics of pharmacy. Advertising] General coverage (Not Table G)QV 737QV 745Drug design. Drug discoveryQV 744QV 771.4Clinical trialsQV 771QV 786.5.C7ColloidsQV 785QV 786.5.C7ColloidsQV 785QV 786.5.C7ColloidsQV 785QV 786.5.C7OlintmentsQV 785QV 786.5.C7OliolsQV 785QV 786.5.C7SolutionsQV 785QV 786.5.C7SolutionsQV 785QV 786.5.C7OliolsQV 785QV 786.5.C8SuppositoriesQV 785QV 786.5.C9OlintmentsQV 785QV 786.5.C8SuppositoriesQV 785QV 786.5.C8SuppositoriesQV 785QV 786.5.C9DintmentsQV 785QV 786.5.C8SuppositoriesQV 785QV 786.5.C9Dintment	WA 520	Peripheral nervous system diseases	WL 500-544
QV 36Receptor pharmacologyQV 38QV 37Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 38.5Biotransformation. PharmacogeneticsQV 38QV 57Nonprescription drugsQV 772QV 151Antihypertensive agents. Calcium channel blockersQV 150QV 632.5Specific hydrocarbons, ArZQV 603QV 633.5Benzene. Benzene derivativesQV 633QV 633.5.84Benzene. Benzene derivativesQV 633QV 633.5.84Benzene. Benzene derivativesQV 633QV 633.5.84Benzene. Konomics of pharmacy. Advertising] GeneralQV 736QV 736.1[Drug industry. Economics of pharmacy. Advertising] GeneralQV 737QV 737.1[Pharmaceutical services. Community pharmacy. Pharmacies]QV 737QV 745Drug design. Drug discoveryQV 744QV 779Drug compoundingQV 785QV 786.5.C3CapsulesQV 785QV 786.5.C4OilisQV 785QV 786.5.C5SolutionsQV 785QV 786.5.C5SolutionsQV 785QV 786.5.C6SolutionsQV 785QV 786.5.C7ColoidsQV 785QV 786.5.C8SuppositoriesQV 785QV 786.5.C9SolutionsQV 785QV 786.5.C6SolutionsQV 785QV 786.5.C7ColoidsQV 785QV 786.5.C8SuppositoriesQV 785QV 786.5.C8SuppositoriesQV 785QV 786.5.C8SuppositoriesQ	WA 510	Trigger points	WE 550
QV 36Receptor pharmacologyQV 38QV 37Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 38.5Biotransformation. PharmacogeneticsQV 38QV 57Nonprescription drugsQV 772QV 151Antihypertensive agents. Calcium channel blockersQV 150QV 604Lists of poisons, antidotes, etc.QV 605QV 633.5Specific hydrocarbons, A-ZQV 633QV 633.5.B4Benzene. Benzene derivativesQV 633QV 633.5.B4Benzene. Benzene derivativesQV 633QV 633.5.B4Ilogenated hydrocarbonsQV 633QV 633.5.B4Ilogenated hydrocarbonsQV 633QV 736.1[Drug industry. Economics of pharmacy. Advertising] General coverage (Not Table G)QV 737QV 745Drug design. Drug discoveryQV 744QV 771.4Clinical trialsQV 771QV 785.5Special dosage forms, A-ZQV 785QV 786.5.7ColoidsQV 772QV 785.5Special dosage forms, A-ZQV 737QV 737.1[Pharmaceutical services. Community pharmacy. Pharmacies] General coverage (Not Table G)QV 778QV 779Drug compoundingQV 778QV 785.5Special dosage forms, A-ZQV 785QV 786.5.7ColoidsQV 785QV 786.5.75SolutionsQV 785QV 786.5.76SolutionsQV 785QV 786.5.77PowdersQV 785QV 786.5.78SuppositoriesQV 785QV 786.5.79 <td< td=""><td>WA 346</td><td>Cutaneous</td><td>WB 340</td></td<>	WA 346	Cutaneous	WB 340
QV 36Receptor pharmacologyQV 38QV 37Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 38.5Biotransformation. PharmacogeneticsQV 38QV 37.0Nonprescription drugsQV 772QV 151Antihypertensive agents. Calcium channel blockersQV 150QV 152Anti-arrhythmia agentsQV 150QV 604Lists of poisons, antidotes, etc.QV 603QV 633.5Specific hydrocarbons, A-ZQV 633QV 633.5.64Benzene. Benzene derivativesQV 633QV 633.5.76Fossil fuelsQV 633QV 736.1[Drug industry. Economics of pharmacy. Advertising] GeneralQV 736QV 737.1[Pharmaceutical services. Community pharmacy. Pharmacies]QV 737QV 745Drug design. Drug discoveryQV 744QV 771.4Clinical trialsQV 778QV 786.5.C3CapsulesQV 785QV 786.5.C4OilsQV 785QV 786.5.C5OiloidsQV 785QV 786.5.C7OiloidsQV 785QV 786.5.C8SolutionsQV 785QV 786.5.C8SolutionsQV 785QV 786.5.C8SolutionsQV 785QV 786.5.C8SolutionsQV 785QV 786.5.C7OiloidsQV 785QV 786.5.C8SolutionsQV 785QV 786.5.C9OintmentsQV 785QV 786.5.C9SolutionsQV 785QV 786.5.C9SolutionsQV 785QV 786.5.C8SolutionsQV	WA 320.1		WA 320
QV 36Receptor pharmacologyQV 38QV 37Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 38.5Biotransformation. PharmacogeneticsQV 38QV 57Nonprescription drugsQV 772QV 151Antihypertensive agents. Calcium channel blockersQV 150QV 604Lists of poisons, antidotes, etc.QV 603QV 633.5Specific hydrocarbons, A-ZQV 633QV 633.5.F6Fossil fuelsQV 633QV 633.5.F6Fossil fuelsQV 633QV 736.1[Drug industry. Economics of pharmacy. Advertising] General coverage (Not Table G)QV 736QV 737.1[Pharmaceutical services. Community pharmacy. Pharmacies] coverage (Not Table G)QV 737QV 745Drug design. Drug discoveryQV 744QV 779Drug compoundingQV 775QV 786.5.C3CapsulesQV 785QV 786.5.C4OilsQV 785QV 786.5.C5OintmentsQV 785QV 786.5.C7OiloidsQV 785QV 786.5.C8SolutionsQV 785QV 786.5.58SuppositoriesQV 785QV 786.5.58SuppositoriesQV 785QV 786.5.58SuppositoriesQV 785	WA 290	Emergency responders	None
QV 36Receptor pharmacologyQV 38QV 37Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 38.5Biotransformation. PharmacogeneticsQV 38QV 57Nonprescription drugsQV 772QV 151Antihypertensive agents. Calcium channel blockersQV 150QV 604Lists of poisons, antidotes, etc.QV 605QV 633.5Specific hydrocarbons, A-ZQV 633QV 633.5.F6Fossil fuelsQV 633QV 736.1[Drug industry. Economics of pharmacy. Advertising] General General coverage (Not Table G)QV 736QV 737.1[Pharmaceutical services. Community pharmacy. Pharmacies] General coverage (Not Table G)QV 778QV 737.1CompoundingQV 778QV 779Drug compoundingQV 778QV 785.5.C3CapsulesQV 785QV 786.5.C4OllsQV 785QV 786.5.C5OintmentsQV 785QV 786.5.C7OintmentsQV 785QV 786.5.79PowdersQV 785, etcQV 786.5.79PowdersQV 785, etcQV 786.5.79PowdersQV 785, etcQV 786.5.79PowdersQV 785, etcQV 786.5.76SolutionsQV 785, etcQV 786.5.76SolutionsQV 785, etcQV 786.5.77PowdersQV 785, etcQV 786.5.79PowdersQV 785, etcQV 786.5.79PowdersQV 785, etcQV 786.5.79SolutionsQV 786, etcQV 786.5.79Solutions	QV 786.5.T3	Tablets	QV 787
QV 36Receptor pharmacologyQV 38QV 37Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 38.5Biotransformation. PharmacogeneticsQV 38QV 57Nonprescription drugsQV 772QV 151Antihypertensive agents. Calcium channel blockersQV 150QV 605Anti-arrhythmia agentsQV 605QV 633.5Specific hydrocarbons, A-ZQV 633QV 633.5.64Benzene. Benzene derivativesQV 633QV 633.5.76Fossil fuelsQV 633QV 736.1[Drug industry. Economics of pharmacy. Advertising] General coverage (Not Table G)QV 737QV 745Drug design. Drug discoveryQV 744QV 771.4Clinical trialsQV 778QV 785.5.73Special dosage forms, A-ZQV 785QV 786.5.74OloidsQV 785QV 737.1[Pharmaceutical services. Community pharmacy. Pharmacies] General coverage (Not Table G)QV 737QV 71.4Clinical trialsQV 771QV 779Drug compoundingQV 778QV 786.5.75Special dosage forms, A-ZQV 785QV 786.5.74ColloidsQV 785QV 786.5.75OilsQV 785QV 786.5.76DintmentsQV 785QV 786.5.77PowdersQV 785QV 786.5.79PowdersQV 785QV 786.5.77DintentsQV 785QV 786.5.77PowdersQV 785QV 786.5.77PowdersQV 785QV 786.5.79Powders <td>QV 786.5.S8</td> <td>Suppositories</td> <td>QV 785, etc.</td>	QV 786.5.S8	Suppositories	QV 785, etc.
QV 36Receptor pharmacologyQV 38QV 37Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 38.5Biotransformation. PharmacogeneticsQV 38QV 57Nonprescription drugsQV 772QV 151Antihypertensive agents. Calcium channel blockersQV 150QV 604Lists of poisons, antidotes, etc.QV 605QV 633.5Specific hydrocarbons, A-ZQV 633QV 633.5.F6Fossil fuelsQV 633QV 633.5.F6Fossil fuelsQV 633QV 736.1[Drug industry. Economics of pharmacy. Advertising] General coverage (Not Table G)QV 736QV 737.1[Pharmaceutical services. Community pharmacy. Pharmacies] General coverage (Not Table G)QV 744QV 771.4Clinical trialsQV 778QV 786.5Special dosage forms, A-ZQV 785QV 786.5.C3CapsulesQV 785QV 786.5.C4OlisQV 785QV 785.5.05OintmentsQV 785	QV 786.5.S6	Solutions	QV 786
QV 36Receptor pharmacologyQV 38QV 37Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 38.5Biotransformation. PharmacogeneticsQV 38QV 57Nonprescription drugsQV 772QV 151Antihypertensive agents. Calcium channel blockersQV 150QV 604Lists of poisons, antidotes, etc.QV 605QV 633.5Specific hydrocarbons, A-ZQV 633QV 633.5.F6Fossil fuelsQV 633QV 633.5.F6Fossil fuelsQV 633QV 736.1[Drug industry. Economics of pharmacy. Advertising] General coverage (Not Table G)QV 737QV 745Drug design. Drug discoveryQV 744QV 779Drug compoundingQV 778QV 786.5.C3CapsulesQV 785QV 786.5.C4CiloidsQV 785QV 786.5.C4OilsQV 785, etc.	QV 786.5.P7	Powders	QV 785, etc.
QV 36Receptor pharmacologyQV 38QV 37Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 38.5Biotransformation. PharmacogeneticsQV 38QV 57Nonprescription drugsQV 772QV 151Antihypertensive agents. Calcium channel blockersQV 150QV 152Anti-arrhythmia agentsQV 150QV 604Lists of poisons, antidotes, etc.QV 605QV 633.5Specific hydrocarbons, A-ZQV 633QV 633.5.F6Fossil fuelsQV 633QV 633.5.H3Halogenated hydrocarbonsQV 633QV 736.1[Drug industry. Economics of pharmacy. Advertising] General coverage (Not Table G)QV 737QV 745Drug design. Drug discoveryQV 744QV 771.4Clinical trialsQV 771QV 785.5.C3Special dosage forms, A-ZQV 785QV 786.5.C3CapsulesCoverage (Not Table G)QV 737	QV 786.5.05	Ointments	QV 785
QV 36Receptor pharmacologyQV 38QV 37Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 38.5Biotransformation. PharmacogeneticsQV 38QV 57Nonprescription drugsQV 772QV 151Antihypertensive agents. Calcium channel blockersQV 150QV 152Anti-arrhythmia agentsQV 605QV 633.5Specific hydrocarbons, A-ZQV 633QV 633.5.F6Fossil fuelsQV 633QV 633.5.F6Fossil fuelsQV 633QV 736.1[Drug industry. Economics of pharmacy. Advertising] General coverage (Not Table G)QV 737QV 745Drug design. Drug discoveryQV 744QV 779Drug compoundingQV 778QV 786.5.C3Special dosage forms, A-ZQV 778QV 786.5.C3CapsulesQV 735	QV 786.5.04	Oils	QV 785, etc.
QV 36Receptor pharmacologyQV 38QV 37Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 38.5Biotransformation. PharmacogeneticsQV 38QV 57Nonprescription drugsQV 772QV 151Antihypertensive agents. Calcium channel blockersQV 150QV 152Anti-arrhythmia agentsQV 605QV 604Lists of poisons, antidotes, etc.QV 605QV 633.5Specific hydrocarbons, A-ZQV 633QV 633.5.F6Fossil fuelsQV 633QV 633.5.F6Fossil fuelsQV 633QV 736.1[Drug industry. Economics of pharmacy. Advertising] General coverage (Not Table G)QV 737QV 745Drug design. Drug discoveryQV 744QV 771.4Clinical trialsQV 771QV 779Drug compoundingQV 778QV 786.5Special dosage forms, A-ZQV 785	QV 786.5.C7	Colloids	QV 785
QV 36Receptor pharmacologyQV 38QV 37Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 38.5Biotransformation. PharmacogeneticsQV 38QV 57Nonprescription drugsQV 772QV 151Antihypertensive agents. Calcium channel blockersQV 150QV 604Lists of poisons, antidotes, etc.QV 605QV 633.5Specific hydrocarbons, A-ZQV 633QV 633.5.F6Fossil fuelsQV 633QV 736.1[Drug industry. Economics of pharmacy. Advertising] General coverage (Not Table G)QV 737QV 745Drug design. Drug discoveryQV 744QV 779Drug compoundingQV 778	QV 786.5.C3	Capsules	QV 785
QV 36Receptor pharmacologyQV 38QV 37Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 38.5Biotransformation. PharmacogeneticsQV 38QV 37.5Nonprescription drugsQV 772QV 151Antihypertensive agents. Calcium channel blockersQV 150QV 152Anti-arrhythmia agentsQV 605QV 604Lists of poisons, antidotes, etc.QV 605QV 633.5Specific hydrocarbons, A-ZQV 633QV 633.5.F6Fossil fuelsQV 633QV 633.5.F6Fossil fuelsQV 633QV 736.1[Drug industry. Economics of pharmacy. Advertising] General General coverage (Not Table G)QV 737QV 745Drug design. Drug discoveryQV 744QV 771.4Clinical trialsQV 771	QV 786.5	Special dosage forms, A-Z	QV 785
QV 36Receptor pharmacologyQV 38QV 37Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 38.5Biotransformation. PharmacogeneticsQV 38QV 57Nonprescription drugsQV 772QV 151Antihypertensive agents. Calcium channel blockersQV 150QV 152Anti-arrhythmia agentsQV 605QV 604Lists of poisons, antidotes, etc.QV 605QV 633.5Specific hydrocarbons, A-ZQV 633QV 633.5.F6Fossil fuelsQV 633QV 633.5.H3Halogenated hydrocarbonsQV 633QV 736.1[Drug industry. Economics of pharmacy. Advertising] General coverage (Not Table G)QV 737QV 745Drug design. Drug discoveryQV 744	QV 779	Drug compounding	QV 778
QV 36Receptor pharmacologyQV 38QV 37Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 38.5Biotransformation. PharmacogeneticsQV 38QV 57Nonprescription drugsQV 772QV 151Antihypertensive agents. Calcium channel blockersQV 150QV 152Anti-arrhythmia agentsQV 150QV 604Lists of poisons, antidotes, etc.QV 605QV 633.5Specific hydrocarbons, A-ZQV 633QV 633.5.F6Fossil fuelsQV 633QV 633.5.H3Halogenated hydrocarbonsQV 633QV 736.1[Drug industry. Economics of pharmacy. Advertising] General coverage (Not Table G)QV 737	QV 771.4	Clinical trials	QV 771
QV 36Receptor pharmacologyQV 38QV 37Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 38.5Biotransformation. PharmacogeneticsQV 38QV 57Nonprescription drugsQV 772QV 151Antihypertensive agents. Calcium channel blockersQV 150QV 152Anti-arrhythmia agentsQV 150QV 604Lists of poisons, antidotes, etc.QV 605QV 633.5Specific hydrocarbons, A-ZQV 633QV 633.5.F6Fossil fuelsQV 633QV 633.5.H3Halogenated hydrocarbonsQV 633QV 736.1[Drug industry. Economics of pharmacy. Advertising] General coverage (Not Table G)QV 737	QV 745		QV 744
QV 36Receptor pharmacologyQV 38QV 37Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 38.5Biotransformation. PharmacogeneticsQV 38QV 57Nonprescription drugsQV 772QV 151Antihypertensive agents. Calcium channel blockersQV 150QV 152Anti-arrhythmia agentsQV 605QV 604Lists of poisons, antidotes, etc.QV 605QV 633.5Specific hydrocarbons, A-ZQV 633QV 633.5.F6Fossil fuelsQV 633QV 633.5.H3Halogenated hydrocarbonsQV 633QV 736.1[Drug industry. Economics of pharmacy. Advertising] GeneralQV 736	QV 737.1		QV 737
QV 36Receptor pharmacologyQV 38QV 37Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 38.5Biotransformation. PharmacogeneticsQV 38QV 57Nonprescription drugsQV 772QV 151Antihypertensive agents. Calcium channel blockersQV 150QV 152Anti-arrhythmia agentsQV 605QV 604Lists of poisons, antidotes, etc.QV 605QV 633.5Benzene. Benzene derivativesQV 633QV 633.5.F6Fossil fuelsQV 633	QV 736.1		QV 736
QV 36Receptor pharmacologyQV 38QV 37Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 38.5Biotransformation. PharmacogeneticsQV 38QV 57Nonprescription drugsQV 772QV 151Antihypertensive agents. Calcium channel blockersQV 150QV 152Anti-arrhythmia agentsQV 605QV 604Lists of poisons, antidotes, etc.QV 605QV 633.5Specific hydrocarbons, A-ZQV 633QV 633.5.B4Benzene. Benzene derivativesQV 633	QV 633.5.H3	Halogenated hydrocarbons	QV 633
QV 36Receptor pharmacologyQV 38QV 37Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 38.5Biotransformation. PharmacogeneticsQV 38QV 57Nonprescription drugsQV 772QV 151Antihypertensive agents. Calcium channel blockersQV 150QV 152Anti-arrhythmia agentsQV 150QV 604Lists of poisons, antidotes, etc.QV 605QV 633.5Specific hydrocarbons, A-ZQV 633	QV 633.5.F6	Fossil fuels	QV 633
QV 36Receptor pharmacologyQV 38QV 37Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 38.5Biotransformation. PharmacogeneticsQV 38QV 57Nonprescription drugsQV 772QV 151Antihypertensive agents. Calcium channel blockersQV 150QV 152Anti-arrhythmia agentsQV 150QV 604Lists of poisons, antidotes, etc.QV 605	QV 633.5.B4	Benzene. Benzene derivatives	QV 633
QV 36Receptor pharmacologyQV 38QV 37Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 38.5Biotransformation. PharmacogeneticsQV 38QV 57Nonprescription drugsQV 772QV 151Antihypertensive agents. Calcium channel blockersQV 150QV 152Anti-arrhythmia agentsQV 150	QV 633.5	Specific hydrocarbons, A-Z	QV 633
QV 36Receptor pharmacologyQV 38QV 37Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 38.5Biotransformation. PharmacogeneticsQV 38QV 57Nonprescription drugsQV 772QV 151Antihypertensive agents. Calcium channel blockersQV 150	QV 604	Lists of poisons, antidotes, etc.	QV 605
QV 36Receptor pharmacologyQV 38QV 37Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 38.5Biotransformation. PharmacogeneticsQV 38QV 57Nonprescription drugsQV 772	QV 152	Anti-arrhythmia agents	QV 150
QV 36Receptor pharmacologyQV 38QV 37Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38QV 38.5Biotransformation. PharmacogeneticsQV 38	QV 151	Antihypertensive agents. Calcium channel blockers	QV 150
QV 36Receptor pharmacologyQV 38QV 37Pharmacological phenomena and processesQV 38QV 37.5Drug interactionsQV 38	QV 57	Nonprescription drugs	QV 772
QV 36Receptor pharmacologyQV 38QV 37Pharmacological phenomena and processesQV 38	QV 38.5	Biotransformation. Pharmacogenetics	QV 38
QV 36 Receptor pharmacology QV 38	QV 37.5	Drug interactions	QV 38
	QV 37	Pharmacological phenomena and processes	QV 38
QV 35 Biopharmaceutics QV 38	QV 36	Receptor pharmacology	QV 38
	QV 35	Biopharmaceutics	QV 38

### QV 34 Experimental pharmacology (General) QV 20.5

NLM Classification 2012 Edition. NLM Technical Bulletin. 2012 May–Jun

QV 235	Dyes	QV 240
QV 618	Irritant poisons	Not applicable
QV 667	Systemic poisons. Paralysants	Not applicable

#### Table G (Geographic Notations)

Changes were made to Table G (Geographic Notations)

- Two (2) Table G numbers were added:
  - South Korea (JK6)
  - North Korea (JK7)
- Korea was moved to the Historical Geographic Locations retaining the same Table G (JK6)

#### Other Changes to the Schedule

Changes were made to other class schedules. For example:

- The schedule outline WQ 200-212 Pregnancy was augmented with Reproduction.
- At WB 495, the caption *Electric stimulation therapy* was augmented with *Magnetic field therapy*.
- At WE 190, Orthopedic procedures was removed from the caption and Traction was added. Orthopedic Procedures is now classed at WE 168.
- At WN 415, Radioisotopes was removed from the caption.
- At WO 62, and anesthesiologist was added to the caption.
- Instructional notes were added or modified to clarify classification practices as needed. For example:
  - A note was added to QT 37: Cf. QU 300-328 Cell engineering.
  - A note was added to WE 168: Classify works on orthopedics as a profession in WE 21.
- Table G (geographic breakdown) is now permitted with WA 320.

All index entries pertaining to the aforementioned schedule additions and changes were modified.

#### Changes to the Index

Eighty-eight (88) new index entries were created of which forty-six (46) are from the 2012 MeSH; the remainder are MeSH terms from previous years. All main index headings are linked to the 2012 vocabulary in the MeSH Browser.

- Karyotype
- Karyotyping
- Krypton Radioisotopes
- Laboratory Personnel
- Magnetic Field Therapy
- Magnetic Fields
- Magnetic Phenomena
- Magnets
- Medical Laboratory Personnel
- Memory, Episodic
- Mercury Compounds
- Metabolic Engineering
- Minority Health
- Musculoskeletal Pain
- Neanderthals
- Neuroimaging
- Noble Gases
- Occupational Injuries
- Osteology
- Pain Management

- Pain Perception
- Particulate Matter
- Pasteurization
- Patient Safety
- Pelvic Floor Disorders
- Peripheral Nerve Injuries
- Pharmacological Processes
- Pharmacopoeias as Topic
- Pharmacovigilance
- Physical Therapists
- Plant Cells
- Plant Pathology
- Plastics
- Polycyclic Hydrocarbons, Aromatic
- Posters
- Propanols
- Proteolysis
- Receptors, Kainic Acid
- Remuneration
- Reproductive Health
- Reproductive Tract Infections
- Sarin
- Serotonin Uptake Inhibitors
- Sex Workers
- Sodium Compounds
- Trigger Points
- Water Quality
- Xenon Radioisotopes
- Yttrium Radioisotopes

Numerous main index entries and cross references were modified to reflect changes in the MeSH vocabulary. For example:

- Mental Retardation was deleted as a main heading and made a cross reference to Intellectual Disability.
- Biological Products was changed to Biological Agents.
- Laboratory Techniques and Procedures was deleted from the index.
- Intervertebral Disk Displacement was changed to Intervertebral Disc Displacement.
- Community Health Aides was deleted as a main heading and made a cross reference to Community Health Workers.

NLM Classification index entries with Library of Congress Classification G (Geography) and L (Education) class numbers were reviewed for accuracy and relevance.

To learn more about the NLM Classification see the Fact Sheet.

By Sharon R. Willis Cataloging Section, Technical Services Division

ISSN 2161-2986 (Online) Content not copyrighted; freely reproducible.

Trademarks Copyright Privacy Accessibility Contact NLM Viewers and Players U.S. National Library of Medicine 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health *NIH...Turning Discovery into Health*® U.S. Department of Health and Human Services Freedom of Information Act

Last updated: 01 November 2013 Permanence level: Permanent: Stable Content